文献速递认知障碍与痴呆

评估克瑞珠单抗与安慰剂在早期阿尔茨海默病成人中的安全性和有效性:两项3期随机安慰剂对照试验

Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials.
PubMed 文献 · JAMA Neurol · 2022-01-01

两项3期多中心随机双盲安慰剂对照平行组研究(CREAD和CREAD2)评估克瑞珠单抗在早期阿尔茨海默病中的安全性和有效性。共随机分配813例(CREAD)和806例(CREAD2)参与者,接受60 mg/kg克瑞珠单抗静脉注射或安慰剂每4周一次至100周。主要终点CDR-SB评分变化在两组间无显著差异(安慰剂减克瑞珠单抗的组间差异为-0.17,95%CI -0.86至0.53,P=0.63)。克瑞珠单抗耐受性良好,但未减少早期AD患者的临床衰退。

要点

  • 克瑞珠单抗60 mg/kg每4周静脉注射在早期AD中耐受性良好。
  • 主要终点CDR-SB评分变化在克瑞珠单抗与安慰剂组间无显著差异。
  • 未观察到AD生物标志物的有意义变化,淀粉样蛋白相关影像异常水肿罕见、轻微且短暂。

核心结论

  • 克瑞珠单抗耐受性良好,但未减少早期阿尔茨海默病参与者的临床衰退。
  • 两项研究均在预设中期分析提示CREAD不太可能达到主要终点后终止。

研究设计与样本

  • 两项3期多中心随机双盲安慰剂对照平行组疗效和安全性研究(CREAD和CREAD2),分别于2016年和2017年启动。
  • CREAD在30个国家的194个中心进行,CREAD2在27个国家的209个中心进行。
  • CREAD筛查3736例,排除2923例后随机分配813例;CREAD2筛查3664例,排除2858例后随机分配806例。
  • 纳入年龄50至85岁的早期AD个体,排除部分合并症及MRI显示脑梗死或超过4个微出血或软脑膜含铁血黄素沉积者。
  • 参与者按1:1随机接受安慰剂或克瑞珠单抗60 mg/kg静脉注射每4周一次至100周。

主要发现

  • CREAD最终分析中安慰剂组409例、克瑞珠单抗组404例;CREAD2中安慰剂组399例、克瑞珠单抗组407例。
  • CREAD第105周CDR-SB评分自基线平均变化组间差异(安慰剂减克瑞珠单抗)为-0.17(95%CI -0.86至0.53;P=0.63)。
  • 与既往试验相比未发现新的安全性信号,淀粉样蛋白相关影像异常水肿罕见、轻微且短暂。
  • 未观察到AD生物标志物的有意义变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 两项研究均在预设中期分析提示CREAD不太可能达到主要终点后终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Alzheimer disease (AD), a neurodegenerative disease characterized by β-amyloid plaques and τ tangles in the brain, represents an unmet medical need with no fully approved therapeutics to modify disease progression. OBJECTIVE: To investigate the safety and efficacy of crenezumab, a humanized monoclonal immunoglobulin G4 antibody targeting β-amyloid oligomers, in participants with prodromal to mild (early) AD. DESIGN, SETTING, AND PARTICIPANTS: Two phase 3 multicenter randomized double-blind placebo-controlled parallel-group efficacy and safety studies of crenezumab in participants with early AD, CREAD and CREAD2, were initiated in 2016 and 2017, respectively, and were designed to evaluate the efficacy and safety of crenezumab in participants with early AD. CREAD (194 sites in 30 countries) and CREAD2 (209 sites in 27 countries) were global multicenter studies. A total of 3736 and 3664 participants were screened in CREAD and CREAD2, respectively. A total of 3736 and 3664 participants were screened in CREAD and CREAD2, respectively. Both trials enrolled individuals aged 50 to 85 years with early AD. Participants with some comorbidities and evidence of cerebral infarction or more than 4 microbleeds or areas of leptomeningeal hemosiderosis on magnetic resonance imaging were excluded. After 2923 and 2858 were excluded, respectively, 813 participants in CREAD and 806 in CREAD2 were randomly assigned in a 1:1 ratio to either placebo or crenezumab. In the final analysis, there were 409 participants in the placebo group and 404 in the crenezumab group in CREAD and 399 in the placebo group and 407 in the crenezumab group in CREAD2. Data were analyzed up until January 2019 and August 2019, respectively. INTERVENTIONS: Participants received placebo or 60 mg/kg crenezumab intravenously every 4 weeks for up to 100 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was change from baseline to week 105 in Clinical Dementia Rating-Sum of Boxes (CDR-SB) score. RESULTS: There were 813 participants in CREAD (mean [SD] age, 70.7 [8.2] years; 483 female and 330 male) and 806 in CREAD2 (mean [SD] age, 70.9 [7.7] years; 456 female and 350 male). Baseline characteristics were balanced between both groups. The between-group difference in mean change from baseline in CDR-SB score (placebo minus crenezumab) was -0.17 (95% CI, -0.86 to 0.53; P = .63) at week 105 in the CREAD study (88 placebo; 86 crenezumab). Compared with previous trials, no new safety signals were identified, and amyloid-related imaging abnormalities with edema were rare, mild, and transient. No meaningful changes in AD biomarkers were observed. Both studies were discontinued following a preplanned interim analysis indicating that CREAD was unlikely to meet the primary end point. CONCLUSIONS AND RELEVANCE: Crenezumab was well tolerated but did not reduce clinical decline in participants with early AD. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: CREAD, NCT02670083; CREAD2, NCT03114657.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Ostrowitzki S, Bittner T, Sink KM, et al. Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials. JAMA Neurol. 2022. PMID: 36121669. doi:10.1001/jamaneurol.2022.2909

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。